Anmeldung erfolgt in Kürze...
Details werden geladen...
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD | The Manila Times
Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.
Ähnliche Seiten
Entera Announces Second Quarter 2026 Financial Results and Business Updates | The Manila Times
https://www.manilatimes.net/2026/08/08/tmt-newswire/globenewswire/entera-announces-second-quarter-2026-financial-results-and-business-updates/2401240Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | The Manila Times
https://www.manilatimes.net/2026/07/31/tmt-newswire/globenewswire/tenax-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update/2395827NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results | The Manila Times
https://www.manilatimes.net/2026/08/05/tmt-newswire/globenewswire/newamsterdam-pharma-provides-corporate-update-and-reports-second-quarter-financial-results/2398827Vroom Announces Second Quarter 2026 Results | The Manila Times
https://www.manilatimes.net/2026/08/05/tmt-newswire/globenewswire/vroom-announces-second-quarter-2026-results/2398420Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update | The Manila Times
https://www.manilatimes.net/2026/08/07/tmt-newswire/globenewswire/spectral-medical-announces-second-quarter-2026-financial-results-and-provides-corporate-update/2400956